Last mentioned: Feb 26, 2026
Functional Cure Declared
Medical reports confirm the patient is effectively cured of the rare disease.
Long-term Follow-up
B.C. patient reports zero attacks one year after single dose.
Phase 1/2 Results
Intellia releases early data showing significant reduction in HAE attacks.
The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
A British Columbia man has been declared functionally cured of Hereditary Angioedema (HAE) following a world-first in-vivo CRISPR gene-editing treatment. The success of Intellia Therapeutics' NTLA-2002 therapy marks a pivotal shift from chronic disease management to permanent genetic correction.